UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients

This study assessed systemic vascular endothelial growth factor (VEGF) level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept.

Free plasma VEGF-A level was measured in this study .

Key Inclusion Criteria

• Newly diagnosed Age-related Macular Degeneration (AMD)
• No previous treatment received for diagnosed AMD
• Visual Acuity 6/7.5 to 6/96

Key Exclusion Criteria:

• standard exclusion criteria for anti-VEGF treatment
• Visual Acuity <6/96
• nAMD in both eyes, or any condition in other eye which may have required anti- VEGF treatment during study period
• other disease in candidate eye which could have compromised visual acuity or required medical/surgical intervention during study period
• participation to other clinical study with 'not approved' treatment within a year prior to UNRAVEL study participation.